Novartis’ Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-s...





